Comparisons

Sermorelin vs CJC-1295

The useful comparison starts with duration. It also needs two clocks: the peptide’s time in blood and the gland’s response.

Amounts used in the studies

Sermorelin half-life

After intravenous administration, Sermorelin’s plasma half-life was on the order of 10–12 minutes. Half-life means the time for the amount in blood to fall by half. Yet growth hormone remained elevated for about 3 hours in the pharmacokinetic study. The study enrolled 30 healthy men and also investigated the intranasal route.

I prefer that mismatch to the familiar claim that a short-lived drug must have a short-lived effect. The pituitary’s response continued after much of the peptide had cleared. Duration has to specify what was measured.

Two time bands compare a roughly 10–12 minute peptide half-life with about 3 hours of elevated growth hormone — Two measures from the intravenous research context in healthy men: plasma half-life and duration of elevated GH. The bands compare time, not treatment effectiveness.

Albumin binding and longer-acting analogs

Sermorelin and CJC-1295 stimulate the GHRH receptor. The long-acting CJC-1295 form with DAC can bind albumin, a blood protein, extending its stay in circulation. That is a different chemical strategy from attaching polyethylene glycol, or PEG, to a GHRH analog. The review of PEGylation describes that second approach, while the GHRH pharmacology review supplies the broader family context.

A comparison needs to specify the CJC-1295 form. The albumin-binding account concerns the DAC version. I’m suspicious of comparisons that quietly drop that qualifier and then rank everything by how long it remains in the blood.

Longer exposure gives a study a different endocrine pattern to investigate. Selecting a winner would also require outcomes and safety data for the population being discussed.

What prolonged stimulation left unresolved

One study of PEG-conjugated GHRH recorded mild, transient injection-site reactions and some impairment of glucose tolerance in elderly subjects with repeated dosing. The compound was a long-acting PEG-conjugated analog. Its findings concern that preparation and study group; they cannot supply a CJC-1295 adverse-event rate.

Continuous infusion adds another complication. In children receiving continuous GHRH(1-29) infusion, an early increase in GH was followed by a decline by 3 to 6 months, with complete suppression in one child. The investigators considered several possible explanations, including antibodies and receptor desensitization. This continuous-infusion result raises a question about pattern as well as duration.

Sermorelin and HGH

Sermorelin stimulates the pituitary; direct HGH supplies the hormone from outside. Walker’s editorial argued for the physiological appeal of stimulating secretion while preserving feedback. There’s an elegance to that physiology that I appreciate. It still needs a comparison trial.

The study amounts page preserves each route and population. For the outcome questions—growth, IGF-1, body fat and memory—the research record is a more useful next stop than another half-life ranking.